Medication Prescribing

The FDA has approved Baqsimi nasal powder, the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection.

The FDA has approved Baqsimi nasal powder, the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection.

The FDA has approved Baqsimi nasal powder, the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection.

A new 3-drug antibacterial drug injection containing an FDA-approved antibiotic and a new β-lactamase inhibitor has been approved.

A new 3-drug antibacterial drug injection containing an FDA-approved antibiotic and a new β-lactamase inhibitor has been approved.

A new 3-drug antibacterial drug injection containing an FDA-approved antibiotic and a new β-lactamase inhibitor has been approved.

The FDA has approved the first treatment option for chronic, inadequately controlled rhinosinusitis with nasal polyps.

The FDA has approved the first treatment option for chronic, inadequately controlled rhinosinusitis with nasal polyps.

The FDA has approved a new option for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.

The FDA has approved a new injection for the treatment of pediatric patients 10 years or older with type 2 diabetes.